We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

73 hedge funds and large institutions have $244M invested in KalVista Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 14

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

60% more capital invested

Capital invested by funds: $153M → $244M (+$91.4M)

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2.98% more ownership

Funds ownership: 73.98% → 76.96% (+3%)

4% less funds holding

Funds holding: 76 → 73 (-3)

Holders
73
Holders Change
-3
Holders Change %
-3.95%
% of All Funds
1.44%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.1%
New
19
Increased
28
Reduced
14
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.68M
2
Franklin Resources
Franklin Resources
California
+$3.7M
3
Victory Capital Management
Victory Capital Management
Texas
+$3.57M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.49M
5
SFM
Sphera Funds Management
Israel
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$10.3M
2
PC
Polar Capital
United Kingdom
-$9.72M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.61M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.01M
5
Neuberger Berman Group
Neuberger Berman Group
New York
-$682K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
26
Samsara BioCapital
California
$2.11M – – –
ACP
27
Acuta Capital Partners
California
$1.92M +$1.08M +82,500 +330%
BCM
28
Bridgeway Capital Management
Texas
$1.08M +$788K +60,400 New
DAM
29
DLD Asset Management
New York
$891K +$653K +50,000 New
BFM
30
Boothbay Fund Management
New York
$779K +$182K +13,924 +47%
Wells Fargo
31
Wells Fargo
California
$773K -$12.2K -934 -2%
N
32
Nuveen
North Carolina
$703K +$95K +7,279 +23%
AA
33
ALPS Advisors
Colorado
$644K +$472K +36,164 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$623K -$24.8K -1,900 -5%
WG
35
Winton Group
United Kingdom
$610K +$447K +34,240 New
Public Sector Pension Investment Board (PSP Investments)
36
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$584K +$428K +32,800 New
Verition Fund Management
37
Verition Fund Management
Connecticut
$553K +$405K +31,065 New
BC
38
Birchview Capital
Vermont
$534K – – –
Charles Schwab
39
Charles Schwab
California
$532K +$33.1K +2,536 +9%
Millennium Management
40
Millennium Management
New York
$501K +$182K +13,929 +98%
Barclays
41
Barclays
United Kingdom
$444K +$89.6K +6,862 +38%
DCM
42
DAFNA Capital Management
California
$440K – – –
PP
43
PDT Partners
New York
$427K +$313K +23,952 New
Goldman Sachs
44
Goldman Sachs
New York
$360K -$351K -26,881 -57%
WMSA
45
Weiss Multi-Strategy Advisers
New York
$356K -$444K -34,000 -63%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$344K +$17.6K +1,350 +8%
JP Morgan Chase
47
JP Morgan Chase
New York
$341K +$200K +15,315 +400%
Morgan Stanley
48
Morgan Stanley
New York
$337K -$253K -19,423 -51%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$312K – – –
UBS Group
50
UBS Group
Switzerland
$310K +$87.2K +6,682 +62%
1
2
3 4

KALV Hedge Fund Activity: Q4 2019 in Review

73 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2019, worth a combined $244M — up 60% from $153M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KALV positions and 17 closed out — a net gain of 2 holders — while 28 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.68M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.3M sold.

  • 73 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2019, down from 76 in Q3 2019.
  • Funds reported $244M of KalVista Pharmaceuticals stock for Q4 2019, up 60% quarter-over-quarter.
  • 19 funds opened new KalVista Pharmaceuticals positions in Q4 2019 and 17 closed out, a net change of +2 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $9.68M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2019 was Deerfield Management, an estimated $10.3M sold.

Based on aggregated 13F filings for Q4 2019.